Boston Scientific price target lowered to $85 from $90 at Truist

Truist lowered the firm’s price target on Boston Scientific (BSX) to $85 from $90 and keeps a Buy rating on the shares after its Q1 results. The company saw decelerating trends in growth for both divisions, but the firm notes that the stock’s valuation is dislocated from its revenue and EPS growth prospects, the analyst tells investors in a research note. Truist adds that following management’s guidance cut, the outlook builds in a “beat and raise potential”.